Effectiveness Of Bnt162b2 (pfizer-biontech) Mrna Vaccination Against Multisystem Inflammatory Syndrome In Children Among Persons Aged 12-18 Years - United States, July-december 2021

Authors

Laura D. Zambrano, Centers for Disease Control and Prevention
Margaret M. Newhams, Children's Hospital Boston
Samantha M. Olson, Centers for Disease Control and Prevention
Natasha B. Halasa, Vanderbilt University Medical Center
Ashley M. Price, Centers for Disease Control and Prevention
Julie A. Boom, Texas Children's Hospital Houston
Leila C. Sahni, Texas Children's Hospital Houston
Satoshi Kamidani, Emory University School of Medicine
Keiko M. Tarquinio, Emory University School of Medicine
Aline B. Maddux, University of Colorado School of Medicine
Sabrina M. Heidemann, Central Michigan University
Samina S. Bhumbra, Indiana University School of Medicine
Katherine E. Bline, Nationwide Children’s Hospital
Ryan A. Nofziger, Akron Children's Hospital
Charlotte V. Hobbs, University of Mississippi Medical Center
Tamara T. Bradford, LSU Health Sciences Center - New OrleansFollow
Natalie Z. Cvijanovich, UCSF Benioff Children's Hospital Oakland
Katherine Irby, Arkansas Children's Hospital
Elizabeth H. MacK, Medical University of South Carolina
Melissa L. Cullimore, Children's Hospital and Medical Center
Pia S. Pannaraj, University of Southern California
Michele Kong, The University of Alabama at Birmingham
Tracie C. Walker, UNC School of Medicine
Shira J. Gertz, Saint Barnabas Medical Center
Kelly N. Michelson, Northwestern University Feinberg School of Medicine
Melissa A. Cameron, Rady Children's Hospital
Kathleen Chiotos, The Children's Hospital of Philadelphia
Mia Maamari, UT Southwestern Medical School

Document Type

Article

Publication Date

1-7-2022

Publication Title

Morbidity and Mortality Weekly Report

First Page

52

Last Page

58

PubMed ID

35025852

Volume

71

Issue

2

Share

COinS